This is a working overview of amino acid sequence, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-02-21 and is reviewed periodically as new material appears.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
| Property | Value | Notes |
|---|---|---|
| Main study model | Rodents, rats and mice | Underpins most of the published data |
| Common routes in studies | Subcutaneous, intraperitoneal, oral | Varies with the experimental design |
| Common analytical method | Reversed-phase HPLC, LC-MS | Used for identity and purity checks |
| Human evidence base | Small | Few trials reported, with limited findings |
| Regulatory status | Varies by jurisdiction | Not an approved medicine in most places |
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
== Host systems == Genes are subjected to heterologous expression often to study specific protein interactions. E. coli, yeast (S. cerevisiae, P. pastoris), immortalized mammalian cells, and amphibian oocytes (i.e. unfertilized eggs) are commonly for studies that require heterologous expression. In choosing a particular system, economic and qualitative aspects have to be considered. Prokaryotic expression is widely used in recombinant DNA technology to form easily manipulated proteins by well-known genetic methods with a low costing medium. Some limitations include intracellular accumulation of heterologous proteins, improper folding of the peptide, lack of post-transcriptional modifications, the potential for product degradation due to traces of protease impurities, and production of endotoxin. Prokaryotic and eukaryotic systems, most commonly bacteria, yeast, insects, and mammalian cells, and occasionally amphibians, fungi, and protists are used for studies that require heterologous expression. Bacteria, especially E. coli, yeast (S. cerevisiae, P. pastoris), insects, and amphibian (oocyte) cells have been used as effective hosts for expressing foreign proteins. Generally, prokaryotes are easier to work with and better understood and are often the preferable host system. It is widely used in recombinant DNA technology to form easily manipulated proteins by well-known genetic methods with a low costing medium. For membrane proteins though, researchers have observed that mammalian cells are more effective.
In a clandestine setting, DMT is not typically synthesized due to the lack of availability of the starting materials, namely tryptamine and oxalyl chloride. Instead, it is more often extracted from plant-sources using a nonpolar hydrocarbon solvent such as naphtha or heptane, and a base such as sodium hydroxide. Alternatively, an acid-base extraction is sometimes used instead. A variety of plants contain DMT at sufficient levels for being viable sources such as Mimosa tenuiflora, Acacia acuminata, Acacia confusa, Acacia maidenii, Arundo donax, 'Diplopterys cabrerana, Psychotria viridis. The chemicals involved in the extraction are commonly available. The plant-material may be illegal to procure in some countries. The end-product (DMT) is illegal in most countries.
Although still under investigation, it now appears that the combination of melamine and cyanuric acid has been linked to the acute renal failure in cats and dogs that have eaten the suspect pet foods...." In the United States, five potential vectors of impact on the human food supply have been identified. The first, which has already been acknowledged to have occurred by FDA and USDA officials, is via contaminated ingredients imported for use in pet foods and sold for use as salvage in animal feed which has been fed to some number of hogs and chickens, the meat from which has been processed and sold to some number of consumers: "There is very low risk to human health" in such cases involving pork and poultry. On 1 May 2007, the FDA and USDA stated that millions of chickens fed feed tainted with contaminated pet food had been consumed by an estimated 2.5 to 3 million people. The second potential vector is via contaminated vegetable proteins imported for intended use as animal feed, which has apparently been acknowledged to occur with regard to fish feed in Canada, while the third possible route is via contaminated vegetable proteins imported for intended use in human food products, and the FDA has issued an import alert subjecting all Chinese vegetable proteins to detention without examination. A fourth potential vector is referred to on 10 May 2007 FDA-USDA press conference, viz. incorporation of contaminated vegetable proteins into products intended for human use and subsequent importation.
Sources: en.wikipedia.org
Large farms: When a digital agriculture technology requires much upfront investment, only large farms with sufficient assets and credit access will adopt it. For example, large farms are most likely to adopt precision agriculture technologies because of high costs. Increasingly however, automated mechanization is focusing on more but smaller autonomous machines, instead of fewer but larger machines such as observed with machines that still require human control. This trend enables smaller farms to participate in digital agriculture more evenly with larger farms, as the upfront investment becomes more equal relative to the size of the farm. Digital divide: The uneven access to information and communication technologies (ICTs) may lead to uneven adoption of, and thereby uneven gains from, digital agriculture. When digital technologies require specific skills, benefits may accrue to digitally literate farmers positioned to take advantage of such opportunities. Gender: Given gender-based disparities in ICT access and the gender gap in agribusiness value chains, men seem more likely to adopt digital agriculture. Therefore, digital technologies could perpetuate gender inequalities in the agricultural sector. Unskilled labor: Advances in on-farm productivity, particularly through digitized automation and precision agriculture, may threaten low-skilled jobs. According to the OECD, agriculture will be one of the sectors most affected by automation and McKinsey Global Institute projects that automation will displace 15% of agricultural workers in Mexico and 30% in Germany.
== Clinical significance == The proteasome and its subunits are of clinical significance for at least two reasons: (1) a compromised complex assembly or a dysfunctional proteasome can be associated with the underlying pathophysiology of specific diseases, and (2) they can be exploited as drug targets for therapeutic interventions. More recently, more effort has been made to consider the proteasome for the development of novel diagnostic markers and strategies. An improved and comprehensive understanding of the pathophysiology of the proteasome should lead to clinical applications in the future. The proteasomes form a pivotal component for the ubiquitin–proteasome system (UPS) and corresponding cellular Protein Quality Control (PQC). Protein ubiquitination and subsequent proteolysis and degradation by the proteasome are important mechanisms in the regulation of the cell cycle, cell growth and differentiation, gene transcription, signal transduction and apoptosis. Proteasome defects lead to reduced proteolytic activity and the accumulation of damaged or misfolded proteins, which may contribute to neurodegenerative disease, cardiovascular diseases, inflammatory responses and autoimmune diseases, and systemic DNA damage responses leading to malignancies.
intensive property A physical quantity whose value does not depend on the size of the system or the quantity of matter for which it is measured. Examples include density, temperature, and pressure. Contrast extensive property.
Sources: en.wikipedia.org
Animal experiments form the bulk of the published record. Rodent models of tendon, ligament, bone, and gut injury are the most common designs. Controlled human trials are rare, which limits confidence in any clinical claim.
They are best described as working hypotheses. Supporting data come mainly from cell cultures and animal tissue, using markers such as growth factors and inflammatory signals. Confirmatory human studies have not been reported.
Status depends on the country. In some places it is treated as a research chemical available without a prescription, while elsewhere it falls under prescription or controlled rules. It holds no general marketing approval as a therapeutic product.
The peptide is synthetic, but its sequence matches a segment of a protein present in human gastric juice. It does not occur as a free fifteen-residue peptide in the body.